Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Prostaglandins Other Lipid Mediat. 2017 Nov 9;134:7–15. doi: 10.1016/j.prostaglandins.2017.11.001

Table 2.

Patient clinical characteristics.

Control
(n=8)		 Unex
(n=10)		 Endo
(n=7)		 PCOS
(n=7)		 DOR
(n=7)
Age 30.00 32.20 31.57 29.29 38.14*
BMI 21.99 21.66 25.23 31.29* 24.34
History of Live Birth 5/8 1/10* 3/7 0/7* 1/7
Number Oocytes Retrieved 18.13 17.20 17.71 19.43 6.71*
Total Blastocyst Number 7.25 5.60 3.00 4.86 2.43*
IVF Cycle Negative HCG 2/8 2/10 2/7 2/7 5/7
IVF Cycle Biochemical or SAB 0/8 1/10 1/7 4/7 0/7
IVF Cycle Ongoing Pregnancy 7/8 7/10 4/7 1/7 3/7

Number of patients is in parenthesis. BMI, Body Mass Index; Unex, Unexplained Infertility; Endo, Endometriosis; PCOS, Polycystic Ovary Syndrome; DOR, Diminished Ovarian Reserve; IVF, in vitro Fertilization; HCG, Human Chorionic Gonadotropin; SAB, Spontaneous Abortion.

*

P<0.05 comparing diagnostic groups versus control group using a student’s t-test and chi-square testing for parametric and non-parametric groups, respectively.